drugset

drugset / Trial / NCT00555724

Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors

NCT00555724 ↗

Phase 1 Completed 40 enrolled Biogen

Non-randomizedSingle-groupOpen-labelTreatment

Summary

Phase 1, open-labeled, dose escalation safety and tolerability study for the treatment of subjects with relapsed or refractory solid tumors.

Timeline

Start: 2008-01
Primary completion: 2010-04
Completion: 2010-07

Publications

Background von Mehren M, Britten CD, Pieslor P, Saville W, Vassos A, Harris S, Galluppi GR, Darif M, Wainberg ZA, Cohen RB, Leong S. A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subjects with relapsed or refractory solid tumors. Invest New Drugs. 2014 Jun;32(3):518-25. doi: 10.1007/s10637-014-0064-y. Epub 2014 Jan 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BIIB022	Monoclonal antibody	—	Intravenous

Indications